Tag - RPHM

Developments

Reneo reaches target enrollment in pivotal trial in primary mitochondrial myopathies

Reneo Pharmaceuticals (NASDAQ:RPHM) achieved its target enrollment of 200 patients in the pivotal STRIDE study of mavodelpar in primary mitochondrial myopathies (PMM). Topline data from the STRIDE study are expected in...

March 14, 2023

Developments

Reneo receives FDA fast track for of long-chain fatty acid oxidation disorder

The FDA granted Reneo Pharmaceuticals’ (NASDAQ:RPHM) mavodelpar (REN001) fast track designation for long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, one of the predominant genotypes in patients with long...

January 31, 2023

Feature

Reneo targeting rare genetic mitochondrial diseases with unmet need

Reneo Pharmaceuticals (NASDAQ:RPHM) is conducting a pivotal Phase 2b clinical trial with its lead asset, REN001, in a rare genetic disease that predominately affects skeletal muscle and reduces life expectancy, with...

January 17, 2023

Markets

Ladenburg starts Reneo Pharma at buy; PT $45

Ladenburg Thalmann initiated coverage of Reneo Pharmaceuticals (NASDAQ:RPHM) with a “buy” rating and price target of $45. The stock closed at $7.99 on Nov. 19. Reneo’s clinical stage asset, REN001 is in development for...

November 22, 2021

Tag - RPHM

Reneo reaches target enrollment in pivotal trial in primary mitochondrial myopathies

Reneo receives FDA fast track for of long-chain fatty acid oxidation disorder

Reneo targeting rare genetic mitochondrial diseases with unmet need

Ladenburg starts Reneo Pharma at buy; PT $45

General

More